Pharmaceutical Executive Digital Edition - February 2011
The Promise Of Translational Medicine
Skipping the Needle: Pharm Exec's Brand of the Year
Novartis' Gilenya is a step forward in treating Multiple Sclerosis. But generating increased compliance is another story
China: Business as UNusual
If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshhot of what's ahead for Big Pharma in the country
Accelerated Evolution
Adapting training techniques is necessary to thrive in the fact-changing dynamic of a physician's office
The Building Block of Drug Discovery
With Francis Collins now calling the shots at NIH, will be be able to deliver on the innovations behind the genome?
Honing Reforms from Clinical Development
Increased efficiency and lower operating costs for both CROs and vendors can be achieved by eliminating activities
Growing Stronger After the Storm
To manage through a resource-constrained environment, it is essential to get the most out of procurement planning
Challenges, Changes, Commitments
The Three Cs could be taxing on FDA resources as the new Congress brings stiffer oversight and leadership revisions to the agency
To Align an Audience, Find a Pulse
All this uncertainty at the back end of drug development is a drain on future therapeutic progress against disease. It's a job killer, too.
Are You Trained to Compete and Win?
With the impact of the sales rep in decline, it's time to beef up training for other pharma functions to fill the gap in a competitive marketplace
